Feasibility of a pharmacy-based overdose prevention program in rural/suburban NY

纽约州农村/郊区基于药房的药物过量预防计划的可行性

基本信息

项目摘要

The purpose of this mixed-methods exploratory study is to (1) investigate the support and diffusion of naloxone pharmacy services that utilize a standing order, and (2) assess feasibility of an expanded public health role for naloxone-registered pharmacists to help increase uptake of pharmacy-acquired naloxone in rural /suburban New York (NY). The U.S. opioid overdose crisis has led to legislation in 49 states allowing naloxone (i.e., opioid overdose reversal medication) to be dispensed through a non-patient specific prescription or “standing order”. In New York State (NYS), over 2,600 pharmacies are registered to participate in the Opioid Overdose Prevention Program (OOPP) which allows use of a standing order to dispense naloxone. Yet, pilot data as well as anecdotal evidence suggests that pharmacy-acquired naloxone is infrequent in NY, and either non-existent or limited in suburban/rural counties where burden of opioid-related overdose deaths is highest. Recent reports have identified pharmacy reimbursement challenges, patient affordability, and patient-anticipated stigma dampening naloxone demand as ongoing barriers – even where extensive pharmacy-targeted overdose prevention training and education have taken place. The goal of this study is to explore barriers (eg. opioid- related stigma) and facilitators (eg. use of a state-funded co-pay reimbursement program) of pharmacy naloxone services in NY suburban/rural counties where pharmacy dispensation is low or non-existent, and overdose rates are high. In addition, we will explore pharmacist interest in coupling naloxone services with other non-stigmatizing pharmacy services to help increase uptake and support of pharmacy naloxone services (a successful stigma- reducing intervention from our prior work in the HIV arena). The diffusion of innovation provides a theoretical framework to examine adoption and rejection of pharmacy naloxone services. Specifically, we will identify pharmacist/pharmacy characteristics, experiences, and practices associated with: (i) naloxone registration status (Aim 1a), (ii) support for pharmacy naloxone services, and (iii) support for coupling naloxone with other non- stigmatizing pharmacy services (Aim 1b) among 1,000 naloxone-registered and non-registered pharmacists. We will also conduct in-depth interviews to contextualize the individual-, pharmacy-, and policy-level barriers/facilitators of pharmacy naloxone services among key stakeholders: (a) pharmacists (n=24); (b) opioid- related ED patients (n=20); and (c) community advocates/health officials (n=16) (Aim 2). We will target 8 counties with the highest opioid overdose rates in NYS to administer a pharmacist computer-assisted phone survey (online, and/or in-person also available), and 2 of those counties will be selected to conduct in-depth interviews where our research capacity has been established. Survey and qualitative data will be analyzed and triangulated for final data interpretation. Proposal significance and innovation is high given: (1) the opioid crisis and similar pharmacy naloxone policy across U.S., (2) the generalizability gained by targeting geographically and racially diverse non-urban areas, and (3) the potential for a pharmacy-based intervention that addresses stigma to follow.
这项混合方法探索性研究的目的是(1)研究纳洛酮的支持和扩散 使用常规订单的药房服务,以及(2)评估公共卫生角色扩大的可行性 纳洛酮注册的药剂师有助于增加农村 /郊区新的药房获得的纳洛酮的吸收 约克(纽约)。美国阿片类药物过量危机已导致49个州允许纳洛酮的立法(即阿片类药物 过量的逆转药物)将通过非患者特定的处方或“常规秩序”来分配。 纽约州(纽约州),有2600多家药房被注册,以参加阿片类药物预防 程序(OOPP),允许使用常规订单来分配纳洛酮。但是,试点数据以及轶事 有证据表明,纽约很少有药房获得的纳洛酮,并且不存在或有限 郊区/农村县的阿片类药物相关过量死亡的燃烧最高。最近的报告有 确定的药房报销挑战,患者的可用性和患者预期的污名 将纳洛酮的需求抑制为持续的障碍 - 即使是大量药房过量的障碍 预防培训和教育已经进行。这项研究的目的是探索障碍(例如,阿片类药物 - 相关的污名)和促进者(例如,使用国家资助的共付款报销计划)药房纳洛酮 纽约郊区/农村县的服务,药房分配较低或不存在,用药费用过量 很高。此外,我们将探索药剂师对将纳洛酮服务与其他非耻辱化耦合的兴趣 药房服务以帮助增加吸收和支持药房纳洛酮服务(成功的污名 - 减少我们先前在艾滋病毒竞技场的工作中的干预措施)。创新的扩散提供了理论上的 检查采用和拒绝药房纳洛酮服务的框架。具体来说,我们将确定 药剂师/药房特征,经验和实践:(i)纳洛酮注册状态 (AIM 1A),(ii)支持药房纳洛酮服务,以及(iii)支持纳洛酮与其他非非 - 在1,000名纳洛酮注册和未注册的药剂师中,污名化药房服务(AIM 1B)。 我们还将进行深入的访谈,以将个人,药房和政策级别的情况下背景化 主要利益相关者中药房纳洛酮服务的障碍/促进者:(a)药剂师(n = 24); (b)阿片类药物 - 相关的ED患者(n = 20); (c)社区拥护者/卫生官员(n = 16)(目标2)。我们将针对8个国家 纽约州阿片类药物过量率最高,以管理药剂师计算机辅助电话调查 (在线和/或面对面的人也可以使用),其中2个县将被选中进行深入的访谈 我们的研究能力已建立。调查和定性数据将进行分析和三角分析 用于最终数据解释。提案意义和创新高度赋予:(1)阿片类药物危机和类似 美国各地的药学纳洛酮政策,(2)针对地理和种族的推广性 潜水员非城市地区,以及(3)基于药房的干预措施的潜力,该干预措施解决了污名。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Rural and small metro area naloxone-dispensing pharmacists' attitudes, experiences, and support for a frontline public health pharmacy role to increase naloxone uptake in New York State, 2019.
  • DOI:
    10.1016/j.jsat.2021.108372
  • 发表时间:
    2021-10
  • 期刊:
  • 影响因子:
    3.9
  • 作者:
    Tofighi B;Lekas HM;Williams SZ;Martino D;Blau C;Lewis CF
  • 通讯作者:
    Lewis CF
Internet use and uptake of a web-based prevention and risk reduction intervention for persons who use drugs in New York City - WebHealth4Us study (2013-2016).
  • DOI:
    10.1080/08897077.2022.2028701
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    3.5
  • 作者:
    Lewis, Crystal Fuller;Williams, Sharifa Z.;Tofighi, Babak;Lekas, Helen-Maria;Joseph, Adriana;Rivera, Alexis;Amesty, Silvia C.
  • 通讯作者:
    Amesty, Silvia C.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CRYSTAL FULLER LEWIS其他文献

CRYSTAL FULLER LEWIS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CRYSTAL FULLER LEWIS', 18)}}的其他基金

Leveraging social determinants via artificial intelligence and peer coaching to address racial disparities in primary care among people who use opioids
通过人工智能和同伴辅导利用社会决定因素来解决阿片类药物使用者初级保健中的种族差异
  • 批准号:
    10829058
  • 财政年份:
    2023
  • 资助金额:
    $ 22.42万
  • 项目类别:
Feasibility of pharmacy-delivered patient navigation + virtual buprenorphine + HIV services
药房提供的患者导航虚拟丁丙诺啡 HIV 服务的可行性
  • 批准号:
    10675653
  • 财政年份:
    2022
  • 资助金额:
    $ 22.42万
  • 项目类别:
Feasibility of pharmacy-delivered patient navigation + virtual buprenorphine + HIV services
药房提供的患者导航虚拟丁丙诺啡 HIV 服务的可行性
  • 批准号:
    10554018
  • 财政年份:
    2022
  • 资助金额:
    $ 22.42万
  • 项目类别:
Feasibility of a pharmacy-based overdose prevention program in rural/suburban NY
纽约州农村/郊区基于药房的药物过量预防计划的可行性
  • 批准号:
    9979522
  • 财政年份:
    2020
  • 资助金额:
    $ 22.42万
  • 项目类别:
Exploratory study of drug user health-related internet and mobile technology use
吸毒者健康相关互联网和移动技术使用的探索性研究
  • 批准号:
    8512442
  • 财政年份:
    2013
  • 资助金额:
    $ 22.42万
  • 项目类别:
Post exposure prophylaxis among IDU syringe customers-Pharmacy pilot intervention
IDU 注射器顾客的暴露后预防——药房试点干预
  • 批准号:
    8679202
  • 财政年份:
    2010
  • 资助金额:
    $ 22.42万
  • 项目类别:
Post exposure prophylaxis among IDU syringe customers-Pharmacy pilot intervention
IDU 注射器顾客的暴露后预防——药房试点干预
  • 批准号:
    8304340
  • 财政年份:
    2010
  • 资助金额:
    $ 22.42万
  • 项目类别:
Post exposure prophylaxis among IDU syringe customers-Pharmacy pilot intervention
IDU 注射器顾客的暴露后预防——药房试点干预
  • 批准号:
    8133982
  • 财政年份:
    2010
  • 资助金额:
    $ 22.42万
  • 项目类别:
Post exposure prophylaxis among IDU syringe customers-Pharmacy pilot intervention
IDU 注射器顾客的暴露后预防——药房试点干预
  • 批准号:
    8513957
  • 财政年份:
    2010
  • 资助金额:
    $ 22.42万
  • 项目类别:
Post exposure prophylaxis among IDU syringe customers-Pharmacy pilot intervention
IDU 注射器顾客的暴露后预防——药房试点干预
  • 批准号:
    8440922
  • 财政年份:
    2010
  • 资助金额:
    $ 22.42万
  • 项目类别:

相似国自然基金

采用新型视觉-电刺激配对范式长期、特异性改变成年期动物视觉系统功能可塑性
  • 批准号:
    32371047
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
破解老年人数字鸿沟:老年人采用数字技术的决策过程、客观障碍和应对策略
  • 批准号:
    72303205
  • 批准年份:
    2023
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
通过抑制流体运动和采用双能谱方法来改进烧蚀速率测量的研究
  • 批准号:
    12305261
  • 批准年份:
    2023
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
采用多种稀疏自注意力机制的Transformer隧道衬砌裂缝检测方法研究
  • 批准号:
    62301339
  • 批准年份:
    2023
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
政策激励、信息传递与农户屋顶光伏技术采用提升机制研究
  • 批准号:
    72304103
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

MRWeight: Medical Residents Learning Weight Management Counseling Skills -- A Multi-Modal, Technology-Assisted, Spaced Education Program
MRWeight:住院医生学习体重管理咨询技能——多模式、技术辅助、间隔教育计划
  • 批准号:
    10561356
  • 财政年份:
    2023
  • 资助金额:
    $ 22.42万
  • 项目类别:
Learning and Living with Wildfire Smoke: Creating Clean Air Environments in Schools through Youth Participatory Action Research
与野火烟雾一起学习和生活:通过青年参与行动研究在学校创造清洁的空气环境
  • 批准号:
    10662674
  • 财政年份:
    2023
  • 资助金额:
    $ 22.42万
  • 项目类别:
Renal transplant Equity through Partnership And Structural Transformation (REPAST)
通过伙伴关系和结构转型实现肾移植公平 (REPAST)
  • 批准号:
    10743661
  • 财政年份:
    2023
  • 资助金额:
    $ 22.42万
  • 项目类别:
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)
明尼苏达大学临床与转化科学研究所 (UMN CTSI)
  • 批准号:
    10763967
  • 财政年份:
    2023
  • 资助金额:
    $ 22.42万
  • 项目类别:
Improving HIV care continuum outcomes among formerly incarcerated individuals through critical time legal interventions
通过关键时刻的法律干预改善前被监禁者的艾滋病毒护理连续结果
  • 批准号:
    10819889
  • 财政年份:
    2023
  • 资助金额:
    $ 22.42万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了